Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
May 7, 2015 7:47 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).
Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... MoreBaird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward
May 6, 2015 6:10 AM EDTBaird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable risk/reward into FDA guidance.
Analyst Brian Skorney commented, "We're jumping back into the stock after last week's NDA submission by potential competitor... More
